Estudio entre 1,53 millones de personas en 113 países entre 2009 y 2021 | Tendencias mundiales en angustia emocional
La prevalencia de sentimientos de angustia emocional aumentó del 25 al 31 % entre 2009 y 2021
La prevalencia de sentimientos de angustia emocional aumentó del 25 al 31 % entre 2009 y 2021
Amar Desai is back at UnitedHealth as senior adviser to its CEO Andrew Witty.
UnitedHealth executive returns to company 6 months after leaving for CVS Read More »
The San Diego-based DNA-sequencing company, which also faces a challenge from European antitrust regulators, said it will appeal the FTC’s order.
Illumina ordered to divest Grail by FTC on anticompetition concerns Read More »
The company aims to expand its position as a workflow solution provider in life science and industrial markets.
Bain acquires Olympus life sciences unit for $3.1B Read More »
The Justice Department on Friday filed to appeal a Thursday ruling by a Texas judge striking down part of the ACA that requires health plans to fully cover certain preventive medical services like HIV and cancer screenings.
Biden administration announces appeal to ACA preventive mandate ruling Read More »
Driving the rate hike is the agency’s decision to phase in the technical risk adjustment changes over three years.
Tidepool Loop, an automated insulin dosing app based on one developed by the DIY diabetes community, received FDA clearance in January.
Grassroots innovation: How a patient-driven device for diabetes won FDA clearance Read More »
Tanto en física como en química, la escala mesoscópica se refiere a la escala de longitud en la que se puede estudiar las propiedades de un material o fenómeno, sin tener que discutir el comportamiento de los átomos individuales. En una modelización mesosc&o …
Predecir la flexibilidad de movimiento del ADN a nivel molecular Read More »
In a potential leap forward for sickle cell disease, Vertex moved closer to launching its one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia.
Vertex and CRISPR Advance First-In-Kind Therapeutic for SCD Read More »
BioNTech will pay Shanghai-based Duality Biologics $170 million upfront for rights to two of its topoisomerase-1 inhibitor-based antibody drug conjugates.
BioNTech Adds Two ADCs in Second Deal in as Many Months Read More »